Association of Spinal Cord Radiomic Features and Disability in Multiple Sclerosis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40947502/
Radiomics identified pathological changes in pwMS in varying stages of the disease course that are undetectable by conventional spinal cord MRI. Radiomics may increase the yield of spinal cord MRI...
Radiomic analysis of spinal cord MRI in multiple sclerosis patients detected pathological changes undetectable by conventional imaging, distinguishing subgroups and correlating with disability more strongly than traditional measures, suggesting biomarker potential.
Target trial emulation to replicate randomised clinical trials using registry data in multiple sclerosis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40908119/
The combined use of a TTE methodology and high-quality registry data is a valid tool to evaluate treatment effectiveness in MS.
This multicentre study used target trial emulation with French MS registry data to replicate eight RCTs of disease-modifying therapies, confirming validity of observational data for real-world treatment effectiveness evaluation.
Risk stratification for disease reactivation after therapy de-escalation/discontinuation in relapsing multiple sclerosis by the VIAADISC score - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40845598/
Risk of disease reactivation after discontinuation from DMF/TERI can be stratified with the VIAADISC score and appears to be safe above age 45-55 and with long-lasting stability. However, risk after...
Proinflammatory Effect of Mesenchymal Stem Cells From Patients With Multiple Sclerosis: Potential Modulation Targets - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40875958/
Our results suggest that blocking ADAM-28 and OPN interaction with cognate receptors or increasing IL-10 reduces the proinflammatory potential of MSCs from people with MS. Similar approaches could be used...
Study shows MSCs from MS patients promote Th17/GM-CSF responses via ADAM28/OPN dysregulation. Natalizumab reduced this proinflammatory effect, underscoring therapeutic relevance of α4β1 blockade and IL-10 modulation in MSC-based MS interventions.
Natalizumab for multiple sclerosis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40767504/
Protocol available via doi.org/10.1002/14651858.CD015123.
Cochrane review of RCTs shows natalizumab significantly reduces relapse risk, disability progression, and MRI activity in RRMS with moderate–high certainty, while benefits in SPMS remain uncertain; safety profile largely comparable to controls.